Darolutamide (ODM-201) in the treatment of nmCRPC

Also on Thursday in San Francisco, Dr. Karim Fizazi presented the initial results from the ARAMIS trial of darolutamide (formerly known as ODM-201) in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

ODM-201 meets Phase III goal in treatment of nmCRPC

Like other, similar drugs before it, ODM-201 — now properly known by the generic name darolutamide — has apparently hit the primary goal of metastasis-free survival in the Phase III ARAMIS trial, as announced yesterday by Bayer and Orion. … READ MORE …

An update on ODM-201 in the treatment of advanced prostate cancer

A while back now (in late 2014) Bayer initiated Phase III trials of the investigational agent ODM-201 — now also known as daralutamide — in the treatment of advanced prostate cancer. … READ MORE …

Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

Phase I/II data on ODM-201 in mCRPC; and a Phase III trial in nmCRPC

ODM-201 is a new androgen receptor  inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …